IDiyas

For the Inventor, By the Inventor

Monroe Township, NJ, United States of America

Shailendra K Saxena

USPTO Granted Patents = 15 

Average Co-Inventor Count = 1.1

ph-index = 4

Forward Citations = 62(Granted Patents)


Location History:

  • West Orange, NJ (US) (2001 - 2009)
  • Monroe Township, NJ (US) (2009 - 2014)

Company Filing History:

goldMedal12 out of 20 
 
Alfacell Corporation
 patents
silverMedal3 out of 6 
 
Tamir Biotechnology, Inc.
 patents

Years Active: 2001-2014

Loading Chart...
15 patents (USPTO):Explore Patents
1. 8808690 - Methods of treating infections originating from viruses in the herpesviridae family (2014-08-19),
2. 8663964 - Methods of treating human papillomavirus (2014-03-04),
3. 8518399 - Methods of treating infections originating from viruses in the herpesviridae family (2013-08-27),
4. 7763449 - Nucleic acid encoding a novel ribonuclease having an amino acid sequence made up of the amino acid sequence of a known ribonuclease and an N-terminal leader sequence that is at least one residue long (2010-07-27),
5. 7585655 - Nucleic acid encoding a fusion protein incorporating a cysteinized ribonuclease (2009-09-08),
6. 7585654 - Nucleic acid encoding cysteinized ribonuclease to which a targeting moiety can be conjugated (2009-09-08),
7. 7556953 - Nucleic acid encoding a novel ribonuclease having an amino acid sequence made up of the amino acid sequence of a known ribonuclease and an N-terminal leader sequence (2009-07-07),
8. 7556952 - Nucleic acid encoding a novel ribonuclease having an amino acid sequence made up of a known amino acid sequence and an initial N-terminal residue (2009-07-07),
9. 7556951 - Nucleic acid encoding a novel ribonuclease having an amino acid sequence made up of the amino acid sequence of a known ribonuclease and an n-terminal leader sequence that is at least one residue long (2009-07-07),
10. 7473542 - Cysteinized ribonuclease and targeting moiety conjugated thereto (2009-01-06),
11. 7442536 - Cysteinized ribonuclease and targeting moiety conjugated thereto (2008-10-28),
12. 7442535 - Fusion protein incorporating a cysteinized ribonuclease (2008-10-28),
13. 7229824 - Ribonucleases and methods of making them recombinantly (2007-06-12),
14. 6423515 - Methods of making nucleic acids encoding ribonucleases (2002-07-23),
15. 6175003 - Nucleic acids encoding ribonucleases and methods of making them (2001-01-16),

Title: Inventor Shailendra K Saxena: A Pioneer in Antiviral Treatments

Introduction

Shailendra K Saxena, based in Monroe Township, NJ, is an accomplished inventor holding a remarkable portfolio of 15 patents. His work primarily revolves around the development of innovative antiviral treatments, addressing critical infections caused by various viruses.

Latest Patents

Among his most recent patents, Saxena has contributed significantly to methods of treating infections originating from viruses in the herpesviridae family. He has explored the efficacy of three ribonucleases (RNases) — ranpirnase, the second embodiment disclosed in U.S. Pat. No. 5,728,805, and recombinant Amphinase-2 — which were tested against identified herpesviridae infections. Quantitative PCR assays have shown that, with some exceptions, these RNases exhibit antiviral activity against a multitude of viruses in this family. Additionally, Saxena has developed methods for treating human papillomavirus (HPV) infections. His research demonstrated that ranpirnase and the second embodiment from U.S. Pat. No. 5,728,805 display antiviral activity against type 11 HPV, as evidenced by QRT-PCR assays.

Career Highlights

Saxena's distinguished career includes contributions to notable organizations in the biotechnology sector. He has worked with Alfacell Corporation and Tamir Biotechnology, Inc., where he has played an instrumental role in advancing antiviral research and developing therapeutic solutions. His extensive experience has positioned him as a recognized figure in both the academic and industry circles regarding viral treatment innovations.

Collaborations

One of Saxena’s notable collaborations includes his work alongside Wojciech J Ardelt, with whom he has shared valuable insights and expertise in the field of antiviral research. This collaborative effort has further enhanced the scope and impact of his innovative work.

Conclusion

Shailendra K Saxena continues to make significant strides in the field of antiviral therapies through his innovative patents and collaborative efforts. His dedication to research and development in combating viral infections places him at the forefront of medical advancements, benefiting countless individuals worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…